subject: Macular Degeneration (amd) And Diabetic Retinopathy Drugs Market [print this page] Macular Degeneration (AMD) and Diabetic Retinopathy Pharmaceutical Market 2010-2025
- what does the future hold for drugs to treat those disorders?
Our new report examines current and future prospects for the age-related macular degeneration (AMD) and diabetic retinopathy (DR) pharmaceutical markets. The global market for AMD and DR drugs exceeded $2.5bn in 2009, with growth from previous years. We predict that the overall market will expand from 2010 onwards. The rising prevalence of AMD and DR is due to aging populations worldwide and other changes. In particular, the world is facing a "diabetes epidemic", with soaring numbers of people with diabetes and related complications, including diabetic retinopathy. ( http://www.bharatbook.com/detail.asp?id=149091&rt=Macular-Degeneration-AMDand-Diabetic-Retinopathy-Pharmaceutical-Market-2010-2025.html )
In particular, Macular Degeneration (AMD) and Diabetic Retinopathy Pharmaceutical Market 2010-2025 covers market prospects for the following agents:
Lucentis
Visudyne
Macugen
Avastin.
Our report examines prospects for the retinal disorders market over the coming 15 years. The commercial success of Lucentis in treating wet AMD illustrates the high rewards for successful treatments. Our analyses reveal that there are commercial opportunities for the treatment of geographic atrophy (advanced dry AMD) and for wet AMD, among other disorders. There is a need for advantages over existing therapies, for improved clinical outcomes and ease of dosing. A large potential market for pharmacological treatment of diabetic retinopathy, AMD and other retinal disorders exists.
Un-met and under-met therapeutic needs provide an impetus to drug developers, with high technological and commercial potential in this sector, our study reveals. What impact will monoclonal antibodies and steroid implants have on the future market? Which products are most likely to meet therapeutic needs in future years? Can newer therapies compete successfully with established treatments? How will Avastin affect the market share of Lucentis, and what are the implications for the future market? Our new report covers such questions, providing the information that you need.
For more information kindly visit : http://www.bharatbook.com/detail.asp?id=149091&rt=Macular-Degeneration-AMDand-Diabetic-Retinopathy-Pharmaceutical-Market-2010-2025.html
